synthetic lethality product pipeline
The latest data show that cancer has become the second leading cause of death in the world causing 10 million people’s death each year globally. There are huge unmet medical needs for cancer treatment. Since foundation in 2009, IMPACT Therapeutics has been dedicated to the discovery and development of novel anti-cancer therapeutics with global rights, building a global leading synthetic lethality product pipeline to address unmet medical needs and make an impact on cancer treatment.
Genomic instability is one of the hallmarks of cancer cells, and the resultant mutations render cancer cells more dependent on alternative pathways for survival and proliferation, so these cancer cells are more vulnerable to targeted perturbations on those alternative pathways – a phenomenon known as synthetic lethality.
Synthetic lethality is an especially attractive and effective approach to targeting some common oncogenes that have been traditionally considered as undruggable. Synthetic lethality also has the potential to overcome the therapeutic resistance caused by new mutations that often occur with the treatment of conventional targeted therapies. Furthermore, therapies addressing synthetic lethality targets can have anti-tumor effects that are complementary to or synergistic with therapeutics employing other mechanisms. Synthetic lethality can be exploited as a drug development approach to selectively target cancer cells with certain mutations, for example, deficiencies in DNA damage response (DDR), and we see this approach usher in a new paradigm for targeted anti-cancer therapy.
Product
Target
Pre-clinical
IND
Ph I
Ph II
Ph III
Marketed
Rights
Collaborations
Senaparib, discovered and developed by IMPACT, is a potent and novel PARP1/2 inhibitor. Its distinctive molecular structure ensures exceptional target selectivity and wide therapeutic window.
The Phase III registrational study (FLAMES) evaluating Senaparib as a first-line maintenance therapy in advanced ovarian cancer patients (all-comers) has met its primary endpoint, and the the results have been published in the internationally renowned medical journal Nature Medicine.
Senaparib Capsules (派舒宁® )has received marketing authorization in China from National Medical Products Administration (NMPA) as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
In June 2023, IMPACT entered into a global license and collaboration agreement with Eikon Therapeutics for PARP1 selective inhibitors including IMP1734. Eikon received an exclusive license from IMPACT to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China.
In December 2023, IMPACT entered into commercial partnership with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a subsidiary of Huadong Medicine Co., Ltd (SZ.000963) for promoting Senaparib. Huadong Medicine received exclusive promotion rights of Senaparib in mainland China.
We intend to continue exploring partnerships through strategic collaborations including licensing arrangements, co-development and co-commercialization arrangements to maximize the clinical and commercial value of our drug candidates.
Senaparib, discovered and developed by IMPACT, is a potent and novel PARP1/2 inhibitor. Its distinctive molecular structure ensures exceptional target selectivity and wide therapeutic window.
The Phase III registrational study (FLAMES) evaluating Senaparib as a first-line maintenance therapy in advanced ovarian cancer patients (all-comers) has met its primary endpoint, and the the results have been published in the internationally renowned medical journal Nature Medicine.
Senaparib Capsules (派舒宁®
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 沪ICP备2024107649号 互联网药品信息证书编号:(沪)-非经营性-2025-0012 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement